SAN
DIEGO, May 3, 2022 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the first quarter 2022 on May 10 at 4:30 p.m.
ET / 1:30 p.m. PT. Dr.
Helen Torley, president, and chief
executive officer, will lead the call. On the same date, Halozyme
will release financial results for the first quarter ended
March 31, 2022, following the close
of trading.
To register for this conference call, please use this link:
https://events.q4inc.com/attendee/321325561. After
registering, you will receive an email confirmation that includes
dial in details and unique conference call codes for entry.
Registration is open through the live call. However, to ensure you
are connected for the full call, we suggest registering a day in
advance or at minimum 10 minutes before the start of the call.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately 15 minutes
prior to the call to register, download and install any necessary
audio software. A telephone replay will be available for two weeks
after the call by dialing (800) 770-2030 (domestic callers) or
(416) 621-4642 (international callers) using replay ID number
89853.
About Halozyme
Halozyme is a biopharmaceutical company
bringing disruptive solutions to significantly improve patient
experiences and outcomes for emerging and established therapies.
Halozyme advises and supports its biopharmaceutical partners in key
aspects of new drug development with the goal of improving
patients' lives while helping its partners achieve global
commercial success. As the innovators of the ENHANZE® technology,
which can reduce hours-long treatments to a matter of minutes,
Halozyme's commercially-validated solution has touched more than
600,000 patient lives in post-marketing use via five commercialized
products across more than 100 global markets. Halozyme and its
world-class partners are currently advancing multiple therapeutic
programs intended to deliver innovative therapies, with the
potential to improve the lives of patients around the globe.
Halozyme's proprietary enzyme rHuPH20 forms the basis of the
ENHANZE® technology and is used to facilitate the delivery of
injected drugs and fluids, potentially reducing the treatment
burden of other drugs to patients. Halozyme has licensed its
ENHANZE® technology to leading pharmaceutical and biotechnology
companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly,
Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV
Healthcare and Chugai Pharmaceutical. Halozyme derives revenues
from these collaborations in the form of milestones and royalties
as the Company's partners make progress developing and
commercializing their products being developed using ENHANZE®.
Halozyme is headquartered in San Diego. For more information
visit Halozyme.com and connect with us on LinkedIn and Twitter.
Contact:
Melinda Hutcheon
Director, Investor Relations and Corporate Communications
858-704-8128
ir@halozyme.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-host-first-quarter-2022-financial-results-webcast-and-conference-call-301538858.html
SOURCE Halozyme Therapeutics, Inc.